Clinical Trial Detail

NCT ID NCT02027935
Title Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Aldesleukin

Cyclophosphamide

Ipilimumab

Age Groups: adult

No variant requirements are available.